Prostate Cancer

Philip Poortmans, MD, PhD, head of Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands, and president of European Society for Therapeutic Radiology and Oncology, discusses the impact of a multidisciplinary approach on survivorship and side effect management for patients with prostate cancer.

An updated analysis of the STAMPEDE trial upholds the survival benefit observed with early use of docetaxel in advanced prostate cancer, but does not support the introduction of zoledronic acid.

USPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.

Anna C. Ferrari, MD, professor, co-director, GU Research Program, Departments of Medicine (Cancer Center) and Medicine (Residency Program), discusses a study that examined the efficacy of LBH589 and bicalutamide in patients with castration-resistant prostate cancer.

Tasquinimod, a drug that showed great promise in phase II trials, failed to improve overall survival in a phase III trial in men with treatment-naïve metastatic castration-resistant prostate cancer.

With the advancement of radium-223 comes questions and controversy regarding optimal treatment sequencing, combination therapy, and appropriate patient selection.

Oliver Sartor, MD, medical oncologist, Tulane University School of Medicine, discusses key points for community oncologists regarding radium-223 for the treatment of prostate cancer.

The alpha particle–emitting radiopharmaceutical radium-223 (Xofigo) is set to expand beyond prostate cancer, given the agent's potent efficacy and mild toxicity profile for patients with osteoblastic metastases.

Medivation has announced that it will purchase the PARP inhibitor talazoparib (BMN-673) from BioMarin Pharmaceutical for $410 million, with additional milestone and royalty payments of up to $160 million.

Joseph F. Renzulli, II, MD, FACS, assistant professor of surgery (urology) clinical, Alpert Medical School, discusses the expanded access program in the United States for radium-223 dichloride in patients with metastatic castration-resistant prostate cancer.

In the urologic oncology field, urologists can play an important role in successful comprehensive care by incorporating palliative care in their treatment regimens.

Concomitant therapy with docetaxel and androgen deprivation therapy initiated at the start of treatment for men with metastatic prostate cancer resulted in an increased survival of 13.6 months compared with men who received ADT alone.

Neal D. Shore, MD, medical director, Carolina Urologic Research Center, managing partner, Atlantic Urology Clinics, discusses preliminary results of the Harris poll, which surveyed how men with advanced prostate cancer communicate with their practitioners.

New diagnoses of prostate cancer cases declined nearly 30% after the United States Preventive Services Task Force recommended against routine prostate-specific antigen screening for men.

Urologists who are in solo practice or not affiliated with a medical school may overuse primary gonadotropin-releasing hormone for men with localized prostate cancer.

Men with intermediate- or high-risk prostate cancer experienced higher survival rates when given increased radiation doses than men with low-risk disease.

Novel combination approaches are currently under exploration that hope to capitalize on the varying mechanisms of action for each newly approved agent for men with metastatic castration-resistant prostate cancer.

Edith Mitchell, MD, Prof of Medicine and Medical Oncology at Thomas Jefferson University, Director of the Center to Eliminate Cancer Disparities at the Sidney Kimmel Cancer Center at Thomas Jefferson University, discusses racial disparities in breast and prostate cancer.

Patients who were taking statins while also undergoing androgen deprivation therapy may experience a reduction in all-cause and prostate cancer-specific deaths.

Joe O'Sullivan, MD, discusses the efficacy of radium-223 when combined with enzalutamide and/or abiraterone in an international early access program for the treatment of patients with metastatic castration-resistant prostate cancer.

Charles J. Ryan, MD, discusses the final survival data for pre-chemotherapy use of abiraterone from the COUGAR-AA-302 study, which demonstrated a median of 35 months for men with castration resistant prostate cancer.

Xiaosong Meng, MD, PhD, NYU Langone Medical Center, discusses MRI-US fusion targeted biopsies and how they can be used to identify high-grade prostate cancers.

Lawrence Karsh, MD, FACS, director, Clinical Research Department, The Urology Center of Colorado, discusses the TERRAIN trial, which compared enzalutamide with bicalutamide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Neal Shore, MD, recently visited the OncLive News Network studios to discuss his role in LUGPA and provide his clinical insights about skeletal complications and the sequencing of radium-223.

A randomized study is underway to determine if the combination of sipuleucel-T (Provenge) and radium-223 (Xofigo) may improve outcomes in patients with metastatic castration-resistant prostate cancer.